Hansa Biopharma AB (HNSA) — Capital Reinvestment Ratio

Latest as of September 2020: 0.14x

Hansa Biopharma AB (HNSA) has a Capital Reinvestment Ratio of 0.14x as of September 2020, meaning it reinvests 0% of its operating cash flow (Skr4.83 Million) in capital expenditures (Skr683.00K). See Hansa Biopharma AB balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.14x
Capex / Operating Cash Flow

Operating Cash Flow

Skr4.83 Million
SEK

Capital Expenditures

Skr683.00K
SEK

Data as of

Sep 2020
Most recent filing

Annual Capital Reinvestment Ratio for Hansa Biopharma AB (None–None)

Year-by-year Capital Reinvestment Ratio for Hansa Biopharma AB from None to None. For live market cap and broader valuation context, see HNSA company net worth.

Year Reinvestment Ratio Operating CF (SEK) Capital Expenditures YoY Change
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow